Blog
Multi-cancer early detection blood tests: promise, limits & next steps
A blood test that looks for signals from several cancers at once is an important research advance. It is not a diagnosis, and it should not replace screening already proven to reduce harm.
Multi-cancer detection tests analyse biological signals in blood — DNA methylation patterns, fragmentation, or other biomarkers — to estimate whether a cancer signal may be present. They make a prediction that requires clinical follow-up. They do not confirm cancer on their own.
What an MCED test is trying to detect
Cancers can shed fragments of DNA and other material into the bloodstream. Different MCED platforms analyse different combinations of these signals, and many also attempt to predict the tissue of origin so that any follow-up can be directed rather than blind.
A positive result requires confirmatory investigation. A negative result cannot rule out every cancer, and does not mean the next twelve months are safe.
The distinction between a screening test and a diagnostic test runs through everything below. A diagnostic test is applied to someone with a reason for concern. A screening test is applied to people with no symptoms at all, which changes how the same result should be interpreted.
Do not trade established screening for a newer blood test
Mammography, cervical screening and colorectal screening have specific age and risk criteria and, importantly, evidence that using them changes outcomes. An MCED test is not a reason to skip any of them.
The first step remains a risk-based screening plan built on age, sex, smoking exposure, family history and personal medical history. That plan is what an additional blood test would supplement.
Related Aquila services
See our health screening options and our pages on multi-cancer early detection and the SPOT-MAS test. These are best discussed as additional options rather than substitutes for conventional screening.
Understanding a positive or negative result
Positive signal
The assay detected a pattern associated with cancer. Imaging, specialist review or other diagnostic testing is needed before any diagnosis exists. A proportion of positives will not turn out to be cancer.
Negative signal
Reduces concern only within the test’s detection limits. Some cancers shed little DNA, early-stage disease is harder to detect, and not every cancer type is covered.
There is a third category worth asking about in advance: indeterminate or inconclusive results, which some platforms report and which can be the most difficult to act on.
Why rarity changes what a positive result means
This is the least intuitive part of screening, and the part that most often surprises people after a positive result.
When a condition is uncommon in the group being tested, most people tested do not have it. Even a test that very rarely flags a healthy person will, across thousands of healthy people, produce a substantial number of false positives — potentially outnumbering the true ones. The same test applied to a high-risk group would perform much better, because there is more real disease to find.
Sensitivity and specificity are properties of the test. The chance that your positive result is real also depends on how common the disease is among people like you. That is why “how accurate is it?” has no single answer.
This is not an argument against MCED testing. It is an argument for knowing, before the sample is taken, that a positive result is a reason to investigate rather than a reason to conclude.
Finding more cancer is not the same as helping more people
For a population screening test the key question is not whether it can find cancer. It is whether using it leads to better outcomes overall — fewer deaths, less late-stage disease — without excessive false alarms, invasive work-ups or overdiagnosis.
False positives trigger scans and biopsies. False negatives create false reassurance. And detecting biologically indolent disease that would never have caused harm exposes people to treatment they did not need — a real phenomenon in several established screening programmes, not a theoretical one.
| Effect | What it means |
|---|---|
| Overdiagnosis | Finding disease that would never have caused symptoms or shortened life, but which is then treated anyway. |
| Lead-time bias | Diagnosing earlier makes survival from diagnosis look longer even if the date of death is unchanged. |
| Length-time bias | Screening preferentially finds slow-growing cancers, which have better outcomes regardless of screening. |
| Work-up harm | Investigations following a positive signal carry their own risks, costs and anxiety. |
These are the reasons a screening test is judged on randomised outcome data rather than on detection rates, and why large studies of multi-cancer screening are still running.
What actually happens after a positive signal
This is worth picturing before ordering, because it is the part people are least prepared for.
A signal suggesting a tissue of origin leads to targeted investigation of that area. A signal without a clear origin can lead to broader imaging, and sometimes to a search that finds nothing while the original signal remains unexplained. That situation — a positive test, a negative work-up and no resolution — is genuinely difficult, and it happens.
Ask in advance who coordinates the follow-up, how quickly it can be arranged, what it costs, and what the plan is if the first round of investigation is clear.
Who might reasonably discuss an MCED test
There is no universal rule. The conversation is more relevant for an older adult, or someone with elevated risk, who understands the uncertainty and is willing to complete follow-up if a signal appears. It is less appropriate for someone who would find an unresolved result intolerable, or who is using it as a substitute for screening they have been putting off.
The decision should also account for what conventional screening has already been done. Someone overdue for colorectal or cervical screening will gain more from completing that than from adding a newer test on top.
Symptoms are a diagnostic question, not a screening one
Unexplained weight loss, bleeding of any kind, a new lump, persistent pain, a change in bowel habit, a persistent cough or difficulty swallowing all require proper diagnostic assessment. A negative screening test in that setting is dangerously reassuring and can delay the investigation that was actually needed.
Plan the follow-up before ordering the test
- Ask which cancers and which biological signals the test covers — and which it does not.
- Understand its reported performance in people similar to you in age and risk.
- Know how the laboratory reports and handles indeterminate results.
- Clarify exactly what imaging or specialist pathway follows a positive signal, and who arranges it.
- Establish the cost of that follow-up, not just of the test.
- Continue age- and risk-appropriate standard screening whatever the result.
Questions patients ask
What is a multi-cancer early detection test?
A blood test analysing signals such as DNA methylation or fragmentation to estimate whether a cancer signal is present, often with a prediction of the likely tissue of origin.
Does a positive result mean I have cancer?
No. It means a pattern associated with cancer was detected, and diagnostic investigation is required. A proportion of positives do not turn out to be cancer.
Does a negative result mean I am cancer-free?
No. It reduces concern only within the test’s detection limits. Some cancers shed little DNA, early disease is harder to detect, and not all types are covered.
Can this replace my mammogram or colonoscopy?
No. Established programmes have evidence that using them changes outcomes. An MCED test is an addition to that plan, not a substitute for it.
How accurate are these tests?
There is no single answer. Sensitivity and specificity belong to the test, but the chance a positive is real also depends on how common the disease is among people like you.
What is overdiagnosis?
Finding disease that would never have caused symptoms or shortened life, and then treating it anyway. It is a documented harm in several established screening programmes.
What happens if the test is positive but investigations find nothing?
That does happen. It usually means continued monitoring and specialist input, and it is genuinely difficult, which is why the follow-up pathway should be understood before testing.
Who coordinates follow-up after a positive signal?
Ask before ordering. You want to know who arranges the imaging or specialist review, how quickly, and what it costs.
I have a symptom — should I take this test?
No. Symptoms need diagnostic assessment. A negative screening result in that setting is falsely reassuring and can delay the right investigation.
Are these tests proven to save lives?
Not yet established. Large studies are evaluating whether multi-cancer screening improves population outcomes, which is the standard a screening test is held to.
Who is most likely to benefit?
Discussion is more relevant for older adults or those at elevated risk who understand the uncertainty and would complete follow-up if a signal appeared.
Should I do this instead of screening I have been putting off?
No — and that is the situation where it helps least. Completing overdue conventional screening has more evidence behind it than adding a newer test.
Sources & further reading
This article is general educational information. MCED tests are evolving rapidly and differ by platform and jurisdiction. A positive result requires diagnostic confirmation, a negative result does not exclude cancer, and symptoms require assessment rather than screening. Content reviewed by the medical team at Aquila Medical Center, Singapore. Last reviewed: 27 August 2026.
Start with your actual cancer risk
A physician can review established screening first, then discuss whether an additional multi-cancer blood test adds useful information for you.